Black Lung Disease Market Research Report - Forecast to 2027

Global Black Lung Disease Market Research Report: By Type (Simple, Complicated), By Diagnosis (Biopsy, Imaging), By Treatment (Oxygen Therapy, Bronchodilators), By End-User (Hospitals & Clinics, Research Organizations, Diagnostic Centers) – Forecast Till 2027

ID: MRFR/Pharma/4256-HCR | | Region: Global | 90 pages

Please note that the assessment period of report has been updated from 2017-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario


Black lung disease or coal workers' pneumoconiosis is caused by long exposure to coal dust and is commonly diagnosed in many of the coal miners. The medical condition is characterized by a progressive building of the inhaled coal dust in the lungs, which may lead to inflammation, fibrosis, necrosis, and others. Increasing prevalence of black lung disease is one of the major drivers of market growth during the forecast period. According to the 2005-2016 report of the Health and Safety Executive, it was estimated that the average number of new cases for black lung disease was 25 (on a yearly basis). Moreover, increasing mining activities, increasing research and development expenses, and rising healthcare expenditures boost the market growth. In 2015, according to the Office for National Statistics, the total healthcare expenditure was estimated to about USD 271 billion within U.K.


However, factors such as lack of awareness, limited availability of medicinal treatment options followed by the high cost of surgical therapeutics including lung transplantation and stem cell therapy are estimated to restrain the market growth during the forecast period. In 2016, the average cost of lung transplantation was expected to be around USD 111, 618.


Global Black Lung Disease Market is expected to grow at an Approximate CAGR of 6.9% during the Forecast Period.


Intended Audience



  • Pharmaceutical Companies

  • Biotechnological Institutes

  • Government and Private Laboratories

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers


Figure 1: - Global Black Lung Disease Market Share, by Region


 Black Lung Disease Market Share


Sources: WHO, Health and Safety Executive, Office for National Statistics, Centers for Disease Control and Prevention, Annual Reports, Press Release, White Paper, And Company Presentation


Segmentation


The global black lung disease market is segmented by the type, diagnosis, treatment, and end-user.


On the basis of the type, the market is segmented into simple coal worker’s pneumoconiosis, complicated coal worker’s pneumoconiosis, and others. On the basis of the diagnosis, the market is segmented into biopsy, imaging, full blood count, pulmonary/lung function tests, physical examination, and others. The imaging segment is segmented into CT, X-ray, and others. On the basis of the treatment, the market is segmented into oxygen therapy, bronchodilators, lung transplant, stem cell therapy, and others. On the basis of the end users, the market is segmented into hospitals & clinics, research organizations & academic institutes, diagnostic centers & labs, and others.


Research Methodology Black Lung Disease Market Research Methodology


Sources: WHO, Health and Safety Executive, Office for National Statistics, Centers for Disease Control and Prevention, Annual Reports, Press Release, White Paper, And Company Presentation


Regional Analysis


The Americas dominate the global black lung disease market owing to a well-developed healthcare sector and huge patient population. Moreover, increasing healthcare expenditure and presence of the key players like GENERAL ELECTRIC and Medtronic within the regions boosts the growth of the market in the Americas. Additionally, developed economies of the region like U.S. and Canada boost.


Europe is the second largest market for black lung disease and is followed by Asia Pacific. Rising government support, huge patient population, and rising healthcare expenditure are some of the major drivers for market growth within the region. On a regional basis, the European black lung disease market is segmented into Western Europe and Eastern Europe. Western Europe is estimated to lead the regional market due to the presence of developed economies like Germany, U.K, France, and others within the region.


Asia Pacific is the fastest growing region for the black lung disease market. Factors such as the presence of a huge patient population, continuously developing healthcare sector, and rising healthcare expenditure drives the market growth within the region. In 2017, a study published in the International Journal of Environmental Research and Public Health journal stated that the number of new cases for pneumoconiosis was about 26,873 in 2014, of which about 13,846 (51.52%) accounted for black lung disease.


The Middle East & Africa has the least share in the global black lung disease market. Presence of poor economies, lack of a developed healthcare sector, stringent government policies, and lack of awareness of the disease, restrain the market growth, especially within the Africa region. A majority of the market of this region is held by the Middle East.


 


Key players in global black lung disease


The key players for the global black lung disease market are Boehringer Ingelheim International GmbH (Germany), GlaxoSmithKline plc (U.K), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), AstraZeneca (U.K), Koninklijke Philips N.V. (The Netherlands), GENERAL ELECTRIC (U.S.), Siemens AG (Germany), TOSHIBA CORPORATION (Japan), Medtronic (U.S.), and others.


 



TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Black Lung Disease Market, by Type

6.1 Introduction

6.2 Simple Coal Worker’s Pneumoconiosis

Market Estimates & Forecast, 2020 – 2027

6.3 Complicated Coal Worker’s Pneumoconiosis

Market Estimates & Forecast, 2020 – 2027

6.4 Others

Chapter 7. Global Black Lung Disease Market, by Diagnosis

7.1 Introduction

7.2 Biopsy

Market Estimates & Forecast, 2020 – 2027

7.3 Imaging

Market Estimates & Forecast, 2020 – 2027

7.3.1 CT

7.3.2 X-ray

7.3.3 Others

7.4 Full Blood Count

Market Estimates & Forecast, 2020 – 2027

7.5 Pulmonary/Lung Function Tests

Market Estimates & Forecast, 2020 – 2027

7.6 Physical Examination

Market Estimates & Forecast, 2020 – 2027

7.7 Others

Chapter 8. Global Black Lung Disease Market, by Treatment

8.1 Introduction

8.2 Oxygen Therapy

Market Estimates & Forecast, 2020 – 2027

8.3 Bronchodilators

Market Estimates & Forecast, 2020 – 2027

8.4 Lung Transplant

Market Estimates & Forecast, 2020 – 2027

8.5 Stem Cell Therapy

Market Estimates & Forecast, 2020 – 2027

8.6 Others

Chapter 9. Global Black Lung Disease Market, by End User

9.1 Introduction

9.2 Hospitals & Clinics

Market Estimates & Forecast, 2020 – 2027

9.3 Research Organizations & Academic Institutes

Market Estimates & Forecast, 2020 – 2027

9.4 Diagnostic Centers & Labs

Market Estimates & Forecast, 2020 – 2027

9.5 Others

Chapter 10. Global Black Lung Disease Market, by Region

10.1 Introduction

10.2 America

10.2.1 North America

10.2.1.1 U.S.

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 U.K.

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

Chapter 11. Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

Chapter 12 Company Profiles

12.1 Boehringer Ingelheim International GmbH

12.1.1 Company Overview

12.1.2 Type Overview

12.1.3 Financials

12.2.4 Key Developments

12.1.5 SWOT Analysis

12.2 GlaxoSmithKline plc

12.2.1 Company Overview

12.2.2 Type Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Novartis AG

12.3.1 Company Overview

12.3.2 Type Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Teva Pharmaceutical Industries Ltd.

12.4.1 Company Overview

12.4.2 Type/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 AstraZeneca

12.5.1 Company Overview

12.5.2 Type Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.6 Koninklijke Philips N.V.

12.6.1 Company Overview

12.6.2 Type Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.7 GENERAL ELECTRIC

12.7.1 Overview

12.7.2 Type Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Siemens AG

12.8.1 Overview

12.8.2 Type Overview

12.8.3 Financials

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.9 TOSHIBA CORPORATION

12.9.1 Overview

12.9.2 Type Overview

12.9.3 Financials

12.9.4 Key Developments

12.9.5 SWOT Analysis

12.10 Medtronic

12.10.1 Overview

12.10.2 Type Overview

12.10.3 Financials

12.10.4 Key Developments

12.10.5 SWOT Analysis

12.11 Others

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Black Lung Disease Market

Chapter 14 Appendix

LIST OF TABLES

Table 1 Black Lung Disease Industry Synopsis, 2020 – 2027

Table 2 Global Black Lung Disease Market Estimates and Forecast, 2020 – 2027, (USD Million)

Table 3 Global Black Lung Disease Market by Region, 2020 – 2027, (USD Million)

Table 4 Global Black Lung Disease Market by Type, 2020 – 2027, (USD Million)

Table 5 Global Black Lung Disease Market by Diagnosis, 2020 – 2027, (USD Million)

Table 6 Global Black Lung Disease Market by Treatment, 2020 – 2027, (USD Million)

Table 7 Global Black Lung Disease Market by End User, 2020 – 2027, (USD Million

Table 8 North America Black Lung Disease Market by Type, 2020 – 2027, (USD Million)

Table 9 North America Black Lung Disease by Diagnosis, 2020 – 2027, (USD Million)

Table 10 North America Black Lung Disease by Treatment, 2020 – 2027, (USD Million)

Table 11 North America Black Lung Disease by End User, 2020 – 2027, (USD Million)

Table 12 U.S. Black Lung Disease Market by Type, 2020 – 2027, (USD Million)

Table 13 U.S. Black Lung Disease Market by Diagnosis, 2020 – 2027, (USD Million)

Table 14 U.S. Black Lung Disease Market by Treatment, 2020 – 2027, (USD Million)

Table 15 U.S. Black Lung Disease Market by End User, 2020 – 2027, (USD Million)

Table 16 Canada Black Lung Disease Market by Type, 2020 – 2027, (USD Million)

Table 17 Canada Black Lung Disease Market by Diagnosis, 2020 – 2027, (USD Million)

Table 18 Canada Black Lung Disease Market by Treatment, 2020 – 2027, (USD Million)

Table 19 Canada Black Lung Disease Market by End User, 2020 – 2027, (USD Million)

Table 20 South America Black Lung Disease Market by Type, 2020 – 2027, (USD Million)

Table 21 South America Black Lung Disease Market by Diagnosis, 2020 – 2027, (USD Million)

Table 22 South America Black Lung Disease Market by Treatment, 2020 – 2027, (USD Million)

Table 23 South America Black Lung Disease Market by End User, 2020 – 2027, (USD Million)

Table 24 Europe Black Lung Disease Market by Type, 2020 – 2027, (USD Million)

Table 25 Europe Black Lung Disease Market by Diagnosis, 2020 – 2027, (USD Million)

Table 26 Europe Black Lung Disease Market by Treatment, 2020 – 2027, (USD Million)

Table 27 Europe Black Lung Disease Market by End User, 2020 – 2027, (USD Million)

Table 28 Western Europe Black Lung Disease Market by Type, 2020 – 2027, (USD Million)

Table 29 Western Europe Black Lung Disease Market by Diagnosis, 2020 – 2027, (USD Million)

Table 30 Western Europe Black Lung Disease Market by Treatment, 2020 – 2027, (USD Million)

Table 31 Western Europe Black Lung Disease Market by End User, 2020 – 2027, (USD Million)

Table 32 Eastern Europe Black Lung Disease Market by Type, 2020 – 2027, (USD Million)

Table 33 Eastern Europe Black Lung Disease Market by Diagnosis, 2020 – 2027, (USD Million)

Table 34 Eastern Europe Black Lung Disease Market by Treatment, 2020 – 2027, (USD Million)

Table 35 Eastern Europe Black Lung Disease Market by End User, 2020 – 2027, (USD Million)

Table 36 Asia Pacific Black Lung Disease Market by Type, 2020 – 2027, (USD Million)

Table 37 Asia Pacific Black Lung Disease Market by Diagnosis, 2020 – 2027, (USD Million)

Table 38 Asia Pacific Black Lung Disease Market by Treatment, 2020 – 2027, (USD Million)

Table 39 Asia Pacific Black Lung Disease Market by End User, 2020 – 2027, (USD Million)

Table 40 The Middle East & Africa Black Lung Disease Market by Type, 2020 – 2027, (USD Million)

Table 41 The Middle East & Africa Black Lung Disease Market by Diagnosis, 2020 – 2027, (USD Million)

Table 42 The Middle East & Africa Black Lung Disease Market by Treatment, 2020 – 2027, (USD Million)

Table 43 The Middle East & Africa Black Lung Disease Market by End User, 2020 – 2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Black Lung Disease Market

Figure 3 Market Dynamics for Global Black Lung Disease Market

Figure 4 Global Black Lung Disease Market Share, by Type 2020

Figure 5 Global Black Lung Disease Market Share, by Diagnosis 2020

Figure 6 Global Black Lung Disease Market Share, by Treatment, 2020

Figure 7 Global Black Lung Disease Market Share, by End User, 2020

Figure 8 Global Black Lung Disease Market Share, by Region, 2020

Figure 9 North America Black Lung Disease Market Share, by Country, 2020

Figure 10 Europe Black Lung Disease Market Share, by Country, 2020

Figure 11 Asia Pacific Black Lung Disease Market Share, by Country, 2020

Figure 12 The Middle East & Africa Black Lung Disease Market Share, by Country, 2020

Figure 13 Global Black Lung Disease Market: Company Share Analysis, 2020 (%)

Figure 14 Boehringer Ingelheim International GmbH: Key Financials

Figure 15 Boehringer Ingelheim International GmbH: Segmental Revenue

Figure 16 Boehringer Ingelheim International GmbH: Geographical Revenue

Figure 17 GlaxoSmithKline plc: Key Financials

Figure 18 GlaxoSmithKline plc: Segmental Revenue

Figure 19 GlaxoSmithKline plc: Geographical Revenue

Figure 20 Novartis AG: Key Financials

Figure 21 Novartis AG: Segmental Revenue

Figure 22 Novartis AG: Geographical Revenue

Figure 23 Teva Pharmaceutical Industries Ltd.: Key Financials

Figure 24 Teva Pharmaceutical Industries Ltd.: Segmental Revenue

Figure 25 Teva Pharmaceutical Industries Ltd.: Geographical Revenue

Figure 26 AstraZeneca: Key Financials

Figure 27 AstraZeneca: Segmental Revenue

Figure 28 AstraZeneca: Geographical Revenue

Figure 29 Koninklijke Philips N.V.: Key Financials

Figure 30 Koninklijke Philips N.V.: Segmental Revenue

Figure 31 Koninklijke Philips N.V.: Geographical Revenue

Figure 32 GENERAL ELECTRIC: Key Financials

Figure 33 GENERAL ELECTRIC: Segmental Revenue

Figure 34 GENERAL ELECTRIC: Geographical Revenue

Figure 35 Siemens AG: Key Financials

Figure 36 Siemens AG: Segmental Revenue

Figure 37 Siemens AG: Geographical Revenue

Figure 38 TOSHIBA CORPORATION: Key Financials

Figure 39 TOSHIBA CORPORATION: Segmental Revenue

Figure 40 TOSHIBA CORPORATION: Geographical Revenue

Figure 41 Medtronic: Key Financials

Figure 42 Medtronic: Segmental Revenue

Figure 43 Medtronic: Geographical Revenue